KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Gross Margin: 2009-2025

Historic Gross Margin for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to 84.41%.

  • Halozyme Therapeutics' Gross Margin rose 145.00% to 84.41% in Q3 2025 from the same period last year, while for Sep 2025 it was 84.55%, marking a year-over-year increase of 246.00%. This contributed to the annual value of 84.30% for FY2024, which is 750.00% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Gross Margin stood at 84.41% for Q3 2025, which was down 1.59% from 85.77% recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Gross Margin high stood at 86.42% for Q1 2022, and its period low was 74.62% during Q3 2023.
  • Moreover, its 3-year median value for Gross Margin was 82.88% (2024), whereas its average is 81.52%.
  • Per our database at Business Quant, Halozyme Therapeutics' Gross Margin crashed by 811bps in 2023 and then skyrocketed by 862bps in 2024.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Gross Margin stood at 78.84% in 2021, then plummeted by 204bps to 76.79% in 2022, then spiked by 47bps to 77.27% in 2023, then surged by 862bps to 85.89% in 2024, then spiked by 145bps to 84.41% in 2025.
  • Its Gross Margin stands at 84.41% for Q3 2025, versus 85.77% for Q2 2025 and 81.73% for Q1 2025.